This company has been marked as potentially delisted and may not be actively trading. Tocagen (TOCA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TOCA vs. ZYME, SBTX, MBX, AVTE, NLTX, CYBN, BIOA, VIRI, WHWK, and OSTXShould you be buying Tocagen stock or one of its competitors? The main competitors of Tocagen include Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), and OS Therapies (OSTX). Tocagen vs. Its Competitors Zymeworks Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics Cybin BioAge Labs Virios Therapeutics Whitehawk Therapeutics OS Therapies Tocagen (NASDAQ:TOCA) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership. Which has more risk and volatility, TOCA or ZYME? Tocagen has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Which has preferable earnings and valuation, TOCA or ZYME? Tocagen has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Tocagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTocagen$40K6,918.57-$63.52M-$2.69-4.30Zymeworks$122.87M8.78-$118.67M-$0.97-14.80 Is TOCA or ZYME more profitable? Zymeworks has a net margin of -182.75% compared to Tocagen's net margin of -176,433.34%. Zymeworks' return on equity of -23.00% beat Tocagen's return on equity.Company Net Margins Return on Equity Return on Assets Tocagen-176,433.34% -327.74% -111.87% Zymeworks -182.75%-23.00%-18.04% Do insiders & institutionals have more ownership in TOCA or ZYME? 21.4% of Tocagen shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 10.9% of Tocagen shares are owned by company insiders. Comparatively, 1.9% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend TOCA or ZYME? Zymeworks has a consensus price target of $21.43, indicating a potential upside of 49.22%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts clearly believe Zymeworks is more favorable than Tocagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tocagen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Zymeworks 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90 Does the media refer more to TOCA or ZYME? In the previous week, Zymeworks had 17 more articles in the media than Tocagen. MarketBeat recorded 17 mentions for Zymeworks and 0 mentions for Tocagen. Zymeworks' average media sentiment score of 0.37 beat Tocagen's score of 0.00 indicating that Zymeworks is being referred to more favorably in the news media. Company Overall Sentiment Tocagen Neutral Zymeworks Neutral SummaryZymeworks beats Tocagen on 13 of the 17 factors compared between the two stocks. Get Tocagen News Delivered to You Automatically Sign up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TOCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TOCA vs. The Competition Export to ExcelMetricTocagenPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$276.74M$852.35M$5.67B$9.82BDividend YieldN/A4.84%3.79%4.07%P/E Ratio-4.881.1930.5825.12Price / Sales6,918.5726.45460.38114.01Price / CashN/A19.5637.4059.05Price / Book25.716.589.096.18Net Income-$63.52M-$4.98M$3.25B$264.89M Tocagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TOCATocagenN/A$11.57+6.9%N/A+3,390.3%$276.74M$40K-4.8877ZYMEZymeworks2.4824 of 5 stars$13.38+2.7%$21.43+60.2%+36.8%$1.01B$122.87M-8.92460SBTXSilverback TherapeuticsN/A$16.66+1.7%N/A+6.9%$600.73MN/A-6.8883High Trading VolumeMBXMBX Biosciences2.5781 of 5 stars$13.66+9.1%$37.63+175.4%N/A$449.92MN/A-2.9536News CoverageAnalyst ForecastAVTEAerovate TherapeuticsN/A$7.40-1.2%N/A-89.2%$214.49MN/A-2.4720Gap UpHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$20.35-4.1%N/A-39.8%$191.25MN/A-6.5490News CoverageGap DownHigh Trading VolumeCYBNCybin2.4511 of 5 stars$7.53-1.3%$85.00+1,028.8%N/A$177.63MN/A-1.7250News CoveragePositive NewsBIOABioAge LabsN/A$4.53+1.1%N/AN/A$162.40M$3.86M0.00N/ANews CoverageVIRIVirios Therapeutics0.107 of 5 stars$4.77-2.5%$5.00+4.8%+2,505.9%$91.86MN/A-17.675WHWKWhitehawk TherapeuticsN/A$1.77+3.5%N/AN/A$83.42M$25.98M-29.5040OSTXOS Therapies2.4501 of 5 stars$1.85+3.7%$18.00+875.6%-41.8%$51.84MN/A-2.15N/ANews CoverageUpcoming Earnings Related Companies and Tools Related Companies Zymeworks Alternatives Silverback Therapeutics Alternatives MBX Biosciences Alternatives Aerovate Therapeutics Alternatives Neoleukin Therapeutics Alternatives Cybin Alternatives BioAge Labs Alternatives Virios Therapeutics Alternatives Whitehawk Therapeutics Alternatives OS Therapies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TOCA) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tocagen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tocagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.